BREAKING SILOS TO TRANSFORM WOMEN’S HEALTH THROUGH MEDTECH Inaugural Summit discusses new evidence in inequities affecting diagnosis, treatment and innovation
With
Jasjit Baveja PhD,
Director of Regulatory and Industry Policy,
Medical Technology Association of Australia (MTAA)
SEGMENT
Filmed in Sydney | July 2026
In an interview with Australian Health Journal, Jasjit Baveja, Director of Regulatory and Industry Policy at the Medical Technology Association of Australia (MTAA), highlighted the growing importance of medical technology in addressing longstanding inequities in women’s health.
Drawing on the outcomes of the inaugural MTAA Women’s Health MedTech Summit, she explained how the event brought together clinicians, researchers, industry leaders, regulators, investors, government representatives and patient advocates to tackle complex challenges through a collaborative approach.
Baveja said the summit was intentionally designed to break down traditional barriers between stakeholders, noting that, “it doesn’t matter who it was, they were all describing different parts of the same problem.” Discussions extended well beyond reproductive and sexual health to examine conditions that affect women exclusively, differently or disproportionately across every stage of life.
The summit identified several key barriers, including delayed diagnosis, gaps in clinical evidence, medical device design that often fails to account for women’s needs, and regulatory and reimbursement challenges. Baveja also highlighted compelling statistics that demonstrate persistent gender disparities in research and healthcare, reinforcing the need for greater investment in women’s health across the entire medical technology lifecycle.
Importantly, she said the discussions reinforced that women’s health is no longer a niche issue, but one with significant health, workforce, economic and innovation implications.
Looking ahead, Baveja said there was “strong support to move from conversation to action,” with MTAA committing to establish a Women’s Health Policy Group and develop a white paper outlining barriers, opportunities and policy recommendations to improve health outcomes for Australian women.
Source: Adapted from transcript
-
Professor Jeffrey Braithwaite on patient safety and health systems improvement
Professor Jeffrey Braithwaite is Founding Director of the Australian Institute of Health Innovation, Director of the Centre for Healthcare Resilience and Implementation Science and Professor of Health Systems Research at Macquarie University.
Professor Jeffrey Braithwaite is a leading health services and systems researcher with an international reputation for his work investigating and contributing to systems improvement.
The Australian Healthcare and Hospitals Association (AHHA) recently announced it will award the 2021 Sidney Sax medal for outstanding contributions to the development and improvement of Australia’s healthcare system to Professor Jeffrey Braithwaite.
-
Confronting picture of growing women’s health crisis in uterine cancers
Uterine cancers have become Australia’s fastest-growing women’s cancer, with incidence doubling over the past 25 years and projected to continue to surge. Without immediate action, more than 44,000 women are expected to be diagnosed by 2035, and 8,900 will lose their lives to the disease.
Released November 2025, Australia’s first State of the Nation: Uterine Cancers in Australia 2025 report by the Australia New Zealand Gynaecological Oncology Group (ANZGOG), reveals a confronting picture of a growing women’s health crisis that has gone largely unseen and one that now requires immediate, coordinated national action.
-
Closing the diagnostic gap in ovarian cancer detection
After 15 years in academia, Associate Professor Michelle Hill founded ProSeek bio to address one of the most urgent challenges in women’s health: closing the diagnostic gap in ovarian cancer.
For too long, women suspected of ovarian cancer have faced an impossible choice — undergo invasive surgery for diagnosis, only for up to 80% of those procedures to reveal no cancer, or delay intervention and risk diagnosis at a later stage when treatment options are fewer and survival outcomes are significantly worse.
